48
Participants
Start Date
January 31, 2005
Primary Completion Date
December 31, 2007
Study Completion Date
December 31, 2007
Volociximab (anti-α5β1 integrin monoclonal antibody)
Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
Site Reference ID/Investigator# 70401, New York
Site Reference ID/Investigator# 70399, Cleveland
Site Reference ID/Investigator# 70400, Los Angeles
Lead Sponsor
Abbott
INDUSTRY